Renfu Pharmaceutical Group is firmly committed to high-quality development.

Release time:

2020-09-15 14:00

Source:

Balancing epidemic prevention and control with enterprise development—“two-pronged approach”

Actively exploring new approaches to modern governance in megacities and promoting high-quality development are the overarching themes running through all our efforts. Faced with the broader context of the pandemic, Renfu Pharmaceutical Group has remained focused on its core business, striving to both effectively control the epidemic and accelerate high-quality development, thereby ensuring the group’s healthy and orderly growth.

　　As the primary reserve and distribution enterprise for emergency supplies in Hubei Province’s COVID-19 prevention and control efforts, and as the supply platform company under the COVID-19 prevention and control command centers at both the Hubei Province and Wuhan City levels, Renfu Pharmaceutical Group went all out during the epidemic to ensure the stockpiling and distribution of防控 materials, thereby providing strong support for Hubei Province and Wuhan City’s emergency supply保障 work.

　　During this critical period of post-pandemic recovery, the companies under Renfu Pharmaceutical Group are turning pressure into motivation, seizing new opportunities amid the crisis, and carrying out their work around three main priorities: revitalizing existing assets, laying out plans for the future, and cultivating talent.

　　Mission accomplished: Taking on the critical responsibility of sourcing, storing, and distributing epidemic prevention supplies.

　　After being assigned on January 21 to join the material support group of the provincial epidemic prevention and control command center, Hubei Renfu Company, a subsidiary of Renfu Pharmaceutical Group, immediately established a leading group for epidemic prevention and control and an emergency command team. They formulated an emergency supply plan for essential materials, a personnel transportation plan, and an emergency inbound and outbound logistics plan, laying a solid foundation for the orderly entry and exit of large quantities of emergency medical supplies in the later stage.

　　On January 23, the Party Committee of Renfu Pharmaceutical Group established a temporary Party branch dedicated to fighting the epidemic and formed a “Pioneer Team of Party Members” that immediately headed to the front lines. Under the leadership of the Pioneer Team of Party Members, volunteer employees from more than 30 member companies of the group assembled into a team of nearly 300 people tasked with procuring and delivering anti-epidemic supplies. Subsequently, the supply-assurance team expanded to nearly a thousand members.

　　Renfu Pharmaceutical Group has fully leveraged its distribution network advantages within Hubei Province, playing a crucial strategic supporting role in the fight against the epidemic by providing medical institutions across Wuhan City and various cities and prefectures in Hubei Province—especially designated hospitals, Huoshenshan Hospital, Leishenshan Hospital, and makeshift hospitals. During the pandemic, the company distributed over 45 million pieces of protective supplies and medical equipment, including masks, protective suits, ventilators, and other essential medical devices. Specifically, it supplied 6.1 million N95 masks, over 24 million surgical masks, more than 14 million ordinary medical masks, over 680,000 protective suits, over 50 tons of disinfectant products, and over 3,000 units of various medical devices such as ventilators and monitors. The company served more than 200 hospitals at Level II and above across Wuhan City and Hubei Province, effectively ensuring that frontline medical personnel had access to the necessary supplies to combat the epidemic.

　　As of now, including international donations, Renfu Pharmaceutical Group and its subsidiaries have cumulatively donated goods and funds totaling nearly 40 million yuan. Together with its controlling shareholder, Contemporary Group, and partner companies, Renfu Pharmaceutical has made total donations valued at over 70 million yuan.

　　Post-pandemic revitalization: Focusing on and persevering with high-quality development.

　　During this critical period of post-pandemic recovery, companies under the Renfu Pharmaceutical Group are turning pressure into motivation, seizing new opportunities amid the crisis. While resuming production and operations, they remain committed to high-quality development. As these enterprises pursue orderly growth, they also help foster the healthy development of upstream and downstream businesses.

　　Yichang Renfu Pharmaceutical is currently Asia’s largest R&D and production base for anesthetic drugs, and the only domestic enterprise capable of developing and manufacturing the entire range of fentanyl products. Recently, the Hubei Provincial Government issued the “Decision on Awarding the 8th Yangtze River Quality Award,” and Yichang Renfu Pharmaceutical was honored with the 2019 8th Hubei Province Yangtze River Quality Award.

　　Recently, Yichang Renfu Pharmaceutical’s Class 1 new drug, remimazolam benzenesulfonate injection, has received a drug registration certificate and been officially approved for market launch. This marks the first Class 1 chemical drug approved in Hubei Province. The approval of this product signifies a milestone leap for Yichang Renfu Pharmaceutical—from following and keeping pace to taking the lead in R&D capabilities.

　　Renfu Puke Pharmaceutical is Hubei Province’s first pharmaceutical formulation export enterprise to obtain U.S. FDA certification. It boasts a world-class soft capsule formulation production facility and quality inspection laboratory that comply with cGMP standards.

[Unite Hearts, Forge Ahead] Renfulikang’s 2020 team-building and outreach activities have concluded successfully.

Guangming Daily: Ensuring Supply, Donating Funds and Supplies—Renfu Pharmaceutical Fights on the Front Lines of the Epidemic Response.